Ding, Ping’an
Guo, Honghai
Sun, Chenyu
Yang, Peigang
Kim, Na Hyun
Tian, Yuan
Liu, Yang
Liu, Pengpeng
Li, Yong
Zhao, Qun
Clinical trials referenced in this document:
Documents that mention this clinical trial
Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study
https://doi.org/10.1186/s12876-022-02199-9
Article History
Received: 27 October 2021
Accepted: 3 March 2022
First Online: 14 March 2022
Declarations
:
: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All patients were informed about the adverse effects accompanying therapies and they all signed informed consent forms. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study design was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University (Approval Number: 2019125).
: Not applicable.
: The authors declare that they have no competing interests.